RPCA
IRON icon

Running Point Capital Advisors’s Disc Medicine IRON Stock Holding History

Running Point Capital Advisors’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$13.5K – 177
2022
Q4 		$13.5K Buy
10,000
+9,667
+2,903% +$481K 0.01% 188
2022
Q3 		$16K Hold
333
– – 0.01% 186
2022
Q2 		$17K Hold
333
– – 0.01% 193
2022
Q1 		$14K Buy
+333
New +$17.5K 0.01% 195

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Running Point Capital Advisors's IRON Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Disc Medicine (IRON) in Q1 2023, closing a stake of 10,000 shares — an estimated $13.5K sold.

Running Point Capital Advisors first reported a position in IRON in Q1 2022 and held it in 4 quarters. The position peaked at $17K in Q2 2022. 45 funds tracked by Wall St. Rank hold IRON as of Q1 2023.

  • Running Point Capital Advisors reported no remaining Disc Medicine position as of Q1 2023 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Disc Medicine shares in Q1 2023, an estimated $13.5K.
  • Running Point Capital Advisors first reported a position in Disc Medicine in Q1 2022 and held it in 4 quarters.
  • Running Point Capital Advisors's Disc Medicine position peaked at $17K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.